Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Merrimack Pharmaceuticals Inc    MACK

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/10/2018 01/11/2018 01/12/2018 01/16/2018 01/17/2018 Date
10.46(c) 10.84(c) 10.74(c) 10.38(c) 10.48(c) Last
143 272 167 011 100 754 115 936 118 532 Volume
+0.29% +3.63% -0.92% -3.35% +0.96% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -88,2 M
Net income 2017 481 M
Finance 2017 86,0 M
Yield 2017 -
Sales 2018 -
EBIT 2018 -91,6 M
Net income 2018 -83,1 M
Finance 2018 173 M
Yield 2018 -
P/E ratio 2017 0,29
P/E ratio 2018
EV / Sales2017 0
EV / Sales2018 0
Capitalization 138 M
More Financials
Company
Merrimack Pharmaceuticals, Inc. engages in discovering, developing and preparing to commercialize innovative medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer.Its offers first commercial product, Onivyde, which is a novel encapsulation of the marketed... 
More about the company
Surperformance© ratings of Merrimack Pharmaceuticals
Trading Rating : Investor Rating : -
More Ratings
Latest news on MERRIMACK PHARMACEUTICALS
01/11 MERRIMACK PHARMACEUTICALS : to Present at the 36th Annual J.P. Morgan Healthcare..
01/04 MERRIMACK PHARMACEUTICALS : Studies from Merrimack Pharmaceuticals Inc. Yield Ne..
01/04 MERRIMACK PHARMACEUTICALS : to Present at the 36th Annual J.P. Morgan Healthcare..
2017 MERRIMACK PHARMACEUTICALS INC : Other Events, Results of Operations and Financia..
2017 MERRIMACK PHARMACEUTICALS : Announces Appointment of George Demetri, M.D., to Bo..
2017 MERRIMACK PHARMACEUTICALS : Announces Appointment of George Demetri, M.D., to Bo..
2017 MERRIMACK PHARMACEUTICALS, INC. (NAS : MACK) Files An 8-K Departure of Directors..
2017 MERRIMACK PHARMACEUTICALS INC : Change in Directors or Principal Officers (form ..
2017 MERRIMACK PHARMACEUTICALS INC : Other Events (form 8-K)
2017 MERRIMACK PHARMACEUTICALS : Receives Orphan Drug Designation for MM-121 for the ..
More news
Sector news : Biotechnology & Medical Research - NEC
08:48a CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
01/08$MACK New Form EFFECT for Merrimack Pharmaceuticals From our Stock News Alert.. 
01/04$MACK Merrimack to Present at the 36th Annual J.P. Morgan Healthcare Conferen..
1
01/02Merrimack Pharmaceuticals Inc $MACK Expected to Post Earnings of -$0.28 Per S.. 
2017Get the latest news and updates for $ALSN $SIR $COGT $RM $MACK automatically .. 
2017TREND REVERSAL UP ALERT: $MACK MERRIMACK PHARMACEUTICALS ? TradeIdeas via
1
More tweets
Qtime:26
News from SeekingAlpha
2017 After Hours Gainers / Losers
2017 Planned equity offering roundup - healthcare
2017 NASDAQ BIOTECH INDEX : 54 to be added, 15 removed
2017 The New Merrimack Is A Possible ROTY Runner For 2018
2017 Merrimack Pharmaceuticals' (MACK) CEO Richard Peters on Q3 2017 Results - Ear..
Chart MERRIMACK PHARMACEUTICALS
Duration : Period :
Merrimack Pharmaceuticals  Technical Analysis Chart | MACK | US5903282094 | 4-Traders
Technical analysis trends MERRIMACK PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 14,5 $
Spread / Average Target 40%
EPS Revisions
Managers
NameTitle
Richard Peters President, Chief Executive Officer & Director
Gary L. Crocker Chairman
Jean M. Franchi Chief Financial Officer
Daryl Drummond Head-Research
Sergio L. Santillana Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
MERRIMACK PHARMACEUTICALS INC4.78%138
CELLTRION, INC.--.--%40 725
IQVIA HOLDINGS INC2.19%20 784
LONZA GROUP1.56%20 682
INCYTE CORPORATION-0.68%19 342
ALNYLAM PHARMACEUTICALS, INC.1.59%12 256